A Phase 1 interventional study of Budesonide Inhalation Suspension and MAP0010 low dose in Asthma, sponsored by Allergan. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-09.
Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 99th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2005, is one of 10 in phase 1, and was the 38th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 6 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
11 studies in Asthma by AbbVie: none open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Asthma by AbbVie, this one is the 10th largest by enrollment, is the only one that started in 2005, is one of 3 in phase 1, and was the 5th registered.
AbbVie’s Asthma studies by the year they started, since 2005.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 11 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose
Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose
Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose
Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose
Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Also known as: Pulmicort Respules®
Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
Time frame: 8 hours
Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010
Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).
Time frame: 8 hours
AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010
The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg\*min/ml).
Time frame: 8 hours
AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010
The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).
Time frame: 8 hours
Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010
Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).
Time frame: 8 hours
| Milestone | Treatment A, B, D, C | Treatment B, C, A, D | Treatment C, D, B, A | Treatment D, A, C, B |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
| pg/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010 | 303.5 ± 177.4 | 106.2 ± 63.47 | 239.9 ± 140.1 | 434.5 ± 246.9 |
Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).
| min | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010 | 9.063 ± 7.122 | 4.467 ± 3.270 | 3.125 ± 1.500 | 3.688 ± 1.448 |
The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg\*min/ml).
| pg*min/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010 | 29040 ± 9316 | 3978 ± 1974 | 8626 ± 4184 | 22130 ± 9675 |
The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).
| pg*min/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010 | 31480 ± 10690 | 4391 ± 1423 | 7842 ± 3647 | 25290 ± 11750 |
Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).
| min | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010 | 145.4 ± 40.84 | 73.02 ± 33.43 | 78.35 ± 27.08 | 140.0 ± 54.19 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/16 (0%) | 4/16 (25%) |
| Treatment B | — | 0/16 (0%) | 4/16 (25%) |
| Treatment C | — | 0/16 (0%) | 3/16 (18.8%) |
| Treatment D | — | 0/16 (0%) | 3/16 (18.8%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| anemiaBlood and lymphatic system disorders | 0/16 | 0/16 | 2/16 | 1/16 |
| dysmenorrhoeaReproductive system and breast disorders | 2/16 | 0/16 | 0/16 | 0/16 |
| thrombophlebitisVascular disorders | 0/16 | 0/16 | 1/16 | 0/16 |
| hematomaVascular disorders | 0/16 | 0/16 | 0/16 | 1/16 |
| epitaxisRespiratory, thoracic and mediastinal disorders | 0/16 | 0/16 | 0/16 | 1/16 |
| pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/16 | 1/16 | 0/16 | 0/16 |
| headacheNervous system disorders | 0/16 | 1/16 | 0/16 | 0/16 |
| herpes simplexInfections and infestations | 0/16 | 1/16 | 0/16 | 0/16 |
| vaginal candidiasisInfections and infestations | 0/16 | 1/16 | 0/16 | 0/16 |
| hordeolumInfections and infestations | 1/16 | 0/16 | 0/16 | 0/16 |
| Age, Continuous(years) | All Patients |
|---|---|
| Mean | 23.3 ± 4.3 |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 8 |
| Male | 8 |
The record gives a start of Dec 2005, a primary completion of Dec 2005 and a completion of May 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide